Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection and recurrence monitoring at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.
The data we and our research colleagues are presenting at ASCO demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes.
Featured presentations demonstrate the use of Guardant's portfolio of blood tests, real-world data and AI to identify genomic and epigenomic biomarkers that can inform treatment decisions across a variety of solid tumor types. Studies also highlight new capabilities of the Guardant360 Liquid test to identify molecular tumor type in carcinomas of unknown primary and confirm the absence of actionable biomarkers, both enabled by the Guardant Infinity™ smart liquid biopsy platform, Presentation highlights include:
Abstract LBA4 plenary session demonstrating the use of the Guardant360® CDx test in detecting emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2- advanced breast cancer in the Phase 3 SERENA-6 trial
Abstract 3504 oral session evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection using Guardant Reveal™ in stage III colon cancer patients after surgery and prior to adjuvant therapy. This study showed a robust prognostic utility of Reveal to identify patients with poorer disease-free and overall survival in a large clinical trial cohort of over 2,000 patients with a median follow-up of 6.1 years.
Abstract 3584 providing analytic and clinical validation of an algorithm to predict the absence of actionable mutations in ctDNA-negative colorectal and non-small cell lung cancer samples, utilizing genomic and epigenomic profiling with the Guardant360 Liquid test.
Abstract 3073 demonstrating application of an epigenomic-based classifier to identify tumor type on liquid biopsy in cancer of unknown primary origin. Study provides validation data for the new molecular tumor type feature of Guardant360 Liquid utilizing DNA methylation signatures across thousands of cancer-specific differentially methylated regions for 14 cancer types.
'The data we and our research colleagues are presenting at ASCO demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'The SERENA-6 study in particular highlights how we are pushing the boundaries of what can be done with liquid biopsy in characterizing disease and potential drug efficacy, providing insights that could potentially change clinical practice.'
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2025 can be found on the ASCO website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit ASCO booth #25077.
Guardant Health and collaborator presentations at ASCO
Saturday, May 31, 9:00 am – 12:00 pm CT
3584/253
Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA
Guardant360 Liquid
4200/490
Circulating tumor DNA-based genomic profiling and real-world outcomes in cancer of unknown primary (CUP)
Guardant360 Liquid
GuardantINFORM
Expand
Saturday, May 31, 1:30 pm – 4:30 pm CT
8528/8
Genomic and circulating tumor DNA landscape in young-onset non-small cell lung cancer
Guardant360 Liquid
8642/122
Use of targeted therapy, healthcare costs, and survival with large panel testing, narrow testing, or no molecular testing in patients with metastatic non-small cell lung cancer (mNSCLC)
Guardant360 Liquid
Guardant360 CDx
10550/275
Validation of a plasma cell-free DNA methylation-based multi-cancer detection test
Shield MCD
Expand
Sunday, June 1, 2:41 pm – 2:53 pm CT (Plenary Session, Hall B1, Live Stream)
LBA4
Oral Clinical Science Symposium: Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial
Guardant360 CDx
Expand
Sunday, June 1, 4:30 pm – 6:00 pm CT (Arie Crown Theater, Live Stream)
1012
Oral Clinical Science Symposium: Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial
Guardant OMNI
Expand
Monday, June 2, 9:00 am – 12:00 pm CT
1052/31
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab
Guardant Reveal
1075/54
Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance
Guardant360 Liquid
5052/251
Evaluating the prognostic utility of cell-free (cf)DNA tumor fraction (TF) in metastatic castration-resistant prostate cancer (mCRPC)
Guardant360 Liquid
5053/252
Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and AR T878A alterations treated with enzalutamide
GuardantINFORM
5077/276
Real-world prevalence of homologous recombination repair alterations (HRRa) and poly (ADP-ribose) polymerase inhibitor (PARPi) use/outcomes in patients (pts) with metastatic prostate cancer (mPC) by race and ethnicity
GuardantINFORM
5086/285
Association between epigenomic biomarkers and baseline clinical characteristics in patients with mCRPC treated with rucaparib in TRITON2
Guardant Infinity
Expand
Monday, June 2, 1:30 pm – 4:30 pm CT
3073/388
Application of an epigenomic-based classifier to identify cancer signal of origin on liquid biopsy in cancer of unknown primary cases
Guardant360 Liquid
3074/389
HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay
Guardant360 Liquid
Expand
5512
Oral Abstract Session: Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA
Guardant Infinity
Expand
Online Abstracts
e20536
Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer
Guardant360 Liquid
e13084
Targeted agents for the treatment of hormone receptor–-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+/HER2- MBC) with co-alterations in ESR1 and AKT pathway: A retrospective analysis
Guardant360 Liquid
Expand
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
an hour ago
- Epoch Times
Wall Street Review: S&P 500 Breaks 6,000 in Broad Market Rally
The rally in U.S. stocks continued to broaden this week, driven by a resilient labor market and easing trade tensions between the United States and China. For the first time since it reached an all-time high in February, the S&P 500 Index retook the 6,000 mark on June 6 and closed up 1.5 percent for the week. The Dow Jones Industrial Average gained 1.17 percent to finish at 42,746. The Nasdaq rose by 2.18 percent to 19,529, while the Russell 2000 rallied 3.19 percent.
Yahoo
an hour ago
- Yahoo
Is CoreWeave Stock a Buy Now?
New AI stock CoreWeave had its initial public offering in March 2025. High demand for AI computing power led to CoreWeave's first-quarter sales soaring more than 400% year over year. The company anticipates sustained revenue growth, but CoreWeave faces financial risks, including operating at a loss. 10 stocks we like better than CoreWeave › Investing in today's stock market can be tricky given the volatile macroeconomic climate, fueled by the Trump administration's ever-shifting tariff policies. But the artificial intelligence sector remains a robust investment opportunity as organizations around the world race to build artificial intelligence (AI) capabilities. Consequently, AI stocks provide the potential for great gains. One example is CoreWeave (NASDAQ: CRWV). The company went public in March at $40 per share. Since then, CoreWeave stock soared to a 52-week high of $166.63 in June. This hot stock remains more than triple its IPO price at the time of this writing. Can it go higher? Evaluating whether now is the time to grab CoreWeave shares requires digging into the company and unpacking its potential as a good investment for the long haul. CoreWeave delivers cloud computing infrastructure to businesses hungry for more computing capacity for their AI systems. The company operates over 30 data centers housing servers and other hardware used by customers to train their AI and develop inference, which is an AI's ability to apply what it learned in training to real-world situations. AI juggernauts such as Microsoft, IBM, and OpenAI, the owner of ChatGPT, are among its roster of customers. The insatiable appetite for AI computing power propelled CoreWeave's business. The company's first-quarter revenue rose a whopping 420% year over year to $981.6 million. Sales growth shows no sign of slowing down. CoreWeave expects Q2 revenue to reach about $1.1 billion. That would represent a strong year-over-year increase of nearly 170% from the prior year's $395 million. The company signs long-term, committed contracts, and as a result, it has visibility into its future revenue potential. At the end of Q1, CoreWeave had amassed a revenue backlog of $25.9 billion, up 63% year over year thanks to a deal with OpenAI. The company forecasts 2025 full-year revenue to come in between $4.9 billion and $5.1 billion, a substantial jump up from 2024's $1.9 billion. Although CoreWeave has enjoyed massive sales success, there are some potential pitfalls with the company. For starters, it isn't profitable. Its Q1 operating expenses totaled $1 billion compared to revenue of $981.6 million, resulting in an operating loss of $27.5 million. Even worse, its costs are accelerating faster than sales, which means the company is moving further away from reaching profitability. CoreWeave's $1 billion in operating expenses represented a 487% increase over the prior year, eclipsing its 420% year-over-year revenue growth. Another area of concern is the company's significant debt load. CoreWeave exited Q1 with $18.8 billion in total liabilities on its balance sheet, and $8.7 billion of that was debt. To keep up with customer demand for computing power, CoreWeave has to spend on expanding and upgrading AI-optimized hardware, and that's not cheap. As it adds customers, the company must expand its data centers to keep pace. Debt is one way it's funding these capital expenditures. Among the risks of buying its stock, CoreWeave admitted, "Our substantial indebtedness could materially adversely affect our financial condition" and that the company "may still incur substantially more indebtedness in the future." In fact, its Q1 debt total of $8.7 billion was a 10% increase from the prior quarter's $7.9 billion in debt. Seeing an increase in both expenses and debt is a concern, but because CoreWeave is a newly public company, there's not much history to know how well it can manage its finances over the long term. Q1 is the only quarter of financial results it's released since its initial public offering. If subsequent quarters reveal a trend toward getting costs and debt under control while continuing to show strong sales growth, CoreWeave stock may prove to be a worthwhile investment over the long run. But for now, only investors with a high risk tolerance should consider buying shares. Even then, another consideration is CoreWeave's stock valuation. This can be assessed by comparing its price-to-sales (P/S) ratio to other AI companies, such as its customer and fellow cloud provider Microsoft and AI leader Nvidia. CoreWeave's share price surged over recent weeks, causing its P/S multiple to skyrocket past that of Nvidia and Microsoft. The valuation suggests CoreWeave stock is overpriced at this time. Although CoreWeave's sales are strong, given its pricey stock and shaky financials, the ideal approach is to put CoreWeave on your watch list. See how it performs over the next few quarters, and wait for its high valuation to drop before considering an investment. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Robert Izquierdo has positions in International Business Machines, Microsoft, and Nvidia. The Motley Fool has positions in and recommends International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Is CoreWeave Stock a Buy Now? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Better Fintech Stock: SoFi Technologies vs. Robinhood Markets
SoFi Technologies' earnings growth is accelerating as it benefits from its expanding slate of personal finance solutions. Shares of Robinhood Markets have hit a new all-time high thanks to its strong growth outlook and improved financial position. 10 stocks we like better than SoFi Technologies › Digital bank SoFi Technologies (NASDAQ: SOFI) and online brokerage Robinhood Markets (NASDAQ: HOOD) both leverage their innovative platforms to disrupt the traditional financial services sector. Their strong growth rates have translated into impressive returns: Shares of SoFi are up 95% in the past year, while Robinhood stock has climbed by a remarkable 246%. After such large gains, some investors may wonder if they can keep their rallies going. Let's consider which of these fintech leaders is a better buy for your portfolio today. SoFi Technologies has transformed from a student and personal loans specialist into a comprehensive financial services platform. Its digital-first, one-stop shop approach resonates with consumers. Today, it serves 10.9 million members, nearly twice as many as it served just two years ago. In the first quarter -- in what CEO Anthony Noto described as a "tremendous start to 2025" -- SoFi's adjusted net revenue surged 33% year over year while adjusted earnings per share (EPS) climbed 200% to $0.06. The bank's success reflects its ongoing diversification beyond lending products into more fee-based services, as its members are increasingly utilizing more of its banking accounts, credit cards, investing options, and other financial products. SoFi is now positioned for more consistently profitable growth and high-quality cash flows. Management expects the positive trends to continue: It's targeting full-year adjusted EPS of $0.27 to $0.28 -- nearly double the $0.15 result in 2024. This outlook highlights a key advantage of SoFi over Robinhood Markets, which faces greater earnings uncertainty, as its business is still tied to transaction volumes and shifting financial market conditions. Investors who are confident in SoFi's ability to execute its growth strategy and capture more market share from legacy banks have compelling reasons to buy and hold the stock for the long term. As robust as SoFi's operating and financial results have been, Robinhood's recent momentum has been even stronger. In the first quarter, net revenue increased 50% while EPS more than doubled to $0.37 from $0.17 in the prior-year period. The company that redefined retail investing with its pioneering commission-free trading model is capitalizing on its 25.8 million funded accounts, where users are trading more actively and directing more of their total assets to the platform. Much of the growth story stems from the cryptocurrency market boom. Crypto now represents 43% of the platform's total transaction volume and contributes 27% of total revenue. Still, Robinhood Markets is also diversifying its product and service offerings with professional-level trading tools, banking solutions, wealth management options, and the premium Robinhood Gold subscription, all of which are increasing the company's customer wallet share. Wall Street has cheered Robinhood's traction, sending the stock up 94% year-to-date to a high that surpassed the pandemic-era peak it set in 2021. Robinhood aims to replicate its U.S. success as it expands globally. It plans to launch service in the Asia Pacific region, and is bolstering its presence in the digital asset space through its recent acquisition of crypto exchange Bitstamp. Those international ambitions, compared to SoFi's more domestically focused operations, could support greater long-term top- and bottom-line growth, which would help justify the stock's premium valuation. Notably, both Robinhood and Sofi are trading at forward price-to-earnings (P/E) ratios near 50, suggesting the market's optimism about their potential is fairly equal. Investors who take the view that Robinhood is just getting started on its path toward a dominant position in the online brokerage space should consider making the stock a part of a diversified portfolio. Choosing which of these is the better fintech stock to buy now isn't easy. I'm bullish on both and predict each will deliver positive returns over the next year. If I were forced to pick just one to buy, though, I'd give the edge to SoFi Technologies, which appears to offer a compelling buy-the-dip opportunity with shares still down about 27% from their 52-week high. In my view, SoFi stands to benefit more from a resilient macroeconomic backdrop, fueling lending demand and earnings growth in the coming quarters, which would provide catalysts for the stock to rally higher. Meanwhile, Robinhood must contend with the lofty expectations baked into its stock price following its recent surge. The market's hopes for it could prove difficult to meet, potentially setting the stage for renewed stock price volatility ahead. Before you buy stock in SoFi Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoFi Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Better Fintech Stock: SoFi Technologies vs. Robinhood Markets was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
